These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33999179)

  • 1. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    Hsu YC; Yeh ML; Wong GL; Chen CH; Peng CY; Buti M; Enomoto M; Xie Q; Trinh H; Preda C; Liu L; Cheung KS; Yeo YH; Hoang J; Huang CF; Riveiro-Barciela M; Kozuka R; Istratescu D; Tsai PC; Accarino EV; Lee DH; Wu JL; Huang JF; Dai CY; Cheung R; Chuang WL; Yuen MF; Wong VW; Yu ML; Nguyen MH
    J Infect Dis; 2021 Dec; 224(11):1890-1899. PubMed ID: 33999179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.
    Hsu YC; Jun DW; Peng CY; Yeh ML; Trinh H; Wong GL; Kim SE; Chen CH; Oh H; Lin CH; Trinh L; Wong VW; Yoon E; Ahn SB; Huang D; Cho YK; Jeong JY; Jeong SW; Kim HS; Xie Q; Liu L; Riveiro-Barciela M; Tsai PC; Accarino EV; Toyoda H; Enomoto M; Preda C; Marciano S; Hoang J; Huang CF; Kozuka R; Yasuda S; Istratescu D; Lee DH; Su JY; Huang YT; Huang JF; Dai CY; Chuang WL; Yuen MF; Gadano A; Cheung R; Lim SG; Buti M; Yu ML; Nguyen MH
    Hepatol Int; 2022 Dec; 16(6):1297-1307. PubMed ID: 36070123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
    Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
    J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
    Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
    Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
    Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
    Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
    Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
    Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 14. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.
    Suzuki F; Suzuki Y; Karino Y; Tanaka Y; Kurosaki M; Yatsuhashi H; Atarashi T; Atsukawa M; Watanabe T; Enomoto M; Kudo M; Maeda N; Kohno H; Joko K; Michitaka K; Miki K; Takahashi K; Ide T; Fujiyama S; Kohno T; Itoh H; Tsukamoto S; Suzuki Y; Kawano Y; Sugiura W; Kumada H
    BMC Gastroenterol; 2021 Dec; 21(1):489. PubMed ID: 34930140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.